Global Hematology Partnering Deals Directory 2010-2021: Access to Over 550 Deals
17 Jun 2021
Dublin, June 17, 2021 (GLOBE NEWSWIRE) -- The "Global Hematology Partnering 2010-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. The Global Hematology Partnering 2010-2021 report provides comprehensive access to available deals and contract documents for over 550 hematology deals.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.The report takes readers through the comprehensive Hematology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Hematology deals.The report presents financial deal terms values for Hematology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.In addition, a comprehensive appendix is provided with each report of all Hematology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report includes deals for the following indications: Agranulocytosis, v, Haemolytic, Iron deficiency, Blood substitute, Disseminated intravascular coagulation (DIC), Hemophilia, Immune thrombocytopenic purpura, Neutropenia, Polycythemia, Thalassemia, Thrombocytopenia, Vitamin K Deficiency, Von-Willebrand disease, plus other hematological indications.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Hematology technologies and products.Report scopeGlobal Hematology Partnering 2010 to 2021 includes:
Available deals and contracts are listed by:
Analyzing actual contract agreements allows assessment of the following:
Key Topics Covered: Executive SummaryChapter 1 - IntroductionChapter 2 - Trends in Hematology dealmaking2.1. Introduction2.2. Hematology partnering over the years 2.3. Hematology partnering by deal type2.4. Hematology partnering by industry sector2.5. Hematology partnering by stage of development2.6. Hematology partnering by technology type2.7. Hematology partnering by therapeutic indicationChapter 3 -Financial deal terms for Hematology partnering3.1. Introduction3.2. Disclosed financials terms for Hematology partnering3.3. Hematology partnering headline values3.4. Hematology deal upfront payments3.5. Hematology deal milestone payments3.6. Hematology royalty ratesChapter 4 - Leading Hematology deals and dealmakers4.1. Introduction4.2. Most active in Hematology partnering4.3. List of most active dealmakers in Hematology 4.4. Top Hematology deals by valueChapter 5 - Hematology contract document directory5.1. Introduction5.2. Hematology partnering deals where contract document availableChapter 6 - Hematology dealmaking by therapeutic target6.1. Introduction6.2. Deals by Hematology therapeutic targetAppendices
Appendix 1 - Directory of Hematology deals by company A-Z 2010 to 2021Appendix 2 - Directory of Hematology deals by deal type 2010 to 2021Appendix 3 - Directory of Hematology deals by stage of development 2010 to 2021Appendix 4 - Directory of Hematology deals by technology type 2010 to 2021
For more information about this report visit
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.